Phase 1, open-label, randomized, single-dose, 3-way crossover trial to compare the pharmacokinetics (PK) of sebetralstat following administration of ODT and the current film-coated tablets in healthy adult volunteers
Latest Information Update: 12 Apr 2023
At a glance
- Drugs Sebetralstat (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 27 Feb 2023 Results comparing the pharmacokinetic characteristics, safety and tolerability of sebetralstat administered as orally disintegrating tablets and film coated tablets in healthy volunteers, presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 07 Nov 2022 New trial record
- 31 Oct 2022 According to KalVista Pharmaceuticals Media Release, KalVista recently completed a clinical trial to investigate the pharmacokinetics of the ODT.